NewAmsterdam Pha SEC Filings

NewAmsterdam Pharma Company N.V. (NAMSW) Rule 144 notice: The filing reports a proposed sale of 100,000 ordinary shares (nominal value EUR 0.12) through ABN AMRO on the Nasdaq Global Market with an aggregate market value of $2,500,000.00. The filer acquired these shares by option exercise on 03/24/2025 from NewAmsterdam Pharma Company N.V., paid in cash on 03/11/2025. The filing shows prior sales by the same person of 50,000 shares on 08/21/2025 for $1,214,613.94 and 50,000 shares on 08/22/2025 for $1,257,092.68. Total shares outstanding are reported as 112,628,458. The filer certifies no undisclosed material adverse information.

Amendment No. 5 to a Schedule 13D reports the current beneficial ownership by a group of Frazier Life Sciences entities in NewAmsterdam Pharma Company N.V. (Ordinary Shares, EUR0.12 par). Together the reporting persons beneficially own 7,327,937 shares (6.5% of the class), which the filing explains consists of 6,827,604 ordinary shares and 500,333 ordinary shares issuable upon exercise of warrants. Key individual holdings disclosed include Sponsor: 3,801,000 shares plus 167,000 warrants; Frazier Life Sciences Public Fund, L.P.: 5,587,957 shares; Frazier Life Sciences Public Overage Fund, L.P.: 2,975,757 shares; Frazier Life Sciences XI, L.P.: 1,174,815 shares; and Frazier Life Sciences XII, L.P.: 59,647 shares. The filing states that working capital funded certain purchases and corrects prior attributions of beneficial ownership for some investment committee members. It also notes no transactions by the reporting persons in the past 60 days except as listed in Exhibit 10.1.

Form 4 filed for James N. Topper, Director of NewAmsterdam Pharma Co. N.V. (NAMSW). The filing reports a securities transaction dated 08/11/2025 and the reporter's related indirect holdings.

On 08/11/2025 the Form 4 shows a transaction with code P reporting the acquisition of 471 ordinary shares at a weighted average price of $23.9787. The filing also discloses indirect holdings of 3,026,604 shares held by Frazier Life Sciences X, L.P. and 3,801,000 shares held by Frazier Lifesciences Sponsor LLC. Footnotes state the purchased shares were bought at prices ranging from $23.91 to $24.00 and include disclaimers that the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form is signed by an attorney-in-fact dated 08/13/2025.

Schedule 13G/A filed for NewAmsterdam Pharma Company N.V. Capital World Investors reports beneficial ownership of 8,387,725 shares, equal to 7.5% of the 112,270,677 shares believed outstanding. The filing states CWI is a division of Capital Research and Management Company and related investment management entities and that these shares are held in the ordinary course of business and not to influence control of the issuer.

The statement shows CWI has sole voting and sole dispositive power over all 8,387,725 shares. The issuer is NewAmsterdam Pharma Company N.V., and CWI's principal business address is 333 South Hope Street, Los Angeles, California. The filing identifies CWI as organized in Delaware.

Forbion-affiliated reporting persons disclosed coordinated holdings in NewAmsterdam Pharma ordinary shares. The combined entity ForGrowth NAP B.V. beneficially owns 10,578,806 Ordinary Shares, representing approximately 9.4% of the outstanding class based on the Issuer's reported share count of 112,628,458. Ownership is reported as shared voting and shared dispositive power for the relevant Forbion entities, while each reporting person reports 0 shares of sole voting or dispositive power. The filing amends prior Schedule 13D disclosures and identifies the allocation of 9,926,633 shares as attributable to Forbion Growth I and Forbion IV through ForGrowth's interest in PoolCo.

This disclosure provides transparency on the size and structure of Forbion's minority stake and the distribution of power among affiliated funds and managers.